Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENDO INTERNATIONAL PLC

(ENDP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo International plc Announces its Qwo (Collagenase Clostridium Histolyticum-Aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

11/22/2021 | 10:53am EST

Endo International plc announced that data from clinical and non-clinical studies of Endo Aesthetics' Qwo? (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, were presented during the annual meeting of the American Society for Dermatologic Surgery (ASDS). INDICATION: QWO is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women. IMPORTANT SAFETY INFORMATION: CONTRAINDICATIONS: QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites. WARNINGS AND PRECAUTIONS: Hypersensitivity Reactions: Serious hypersensitivity reactions including anaphylaxis have been reported with the use of collagenase clostridium histolyticum. If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions. Injection Site Bruising: In clinical trials, 84% of subjects treated with QWO experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking =150 mg aspirin daily) were excluded from participating in Trials 1 and 2. QWO should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet (except those taking =150 mg aspirin daily) or anticoagulant therapy. Substitution of Collagenase Products: QWO must not be substituted with other injectable collagenase products. QWO is not intended for the treatment of Peyronie's Disease or Dupuytren's Contracture. ADVERSE REACTIONS: In clinical trials, the most commonly reported adverse reactions in patients treated with QWO incidence = 10% were at the injection site: bruising, pain, nodule and pruritus.


ę S&P Capital IQ 2021
All news about ENDO INTERNATIONAL PLC
01/19MARKETSCREENER’S WORLD PRESS REVIEW : January 19, 2022
01/18Endo International Reaches Settlement With Florida Over Opioid Claims
MT
01/18Drugmaker Endo signs $65 million opioid settlement with Florida
RE
01/18Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims
PR
01/17Paladin Labs Announces the Launch of Xydalba« (dalbavancin for injection) in Canada
AQ
01/13Endo Announces Publication of New AVEED« (testosterone undecanoate) Data in Peer-Review..
PR
01/13Endo Announces Publication of New AVEED« (testosterone undecanoate) Data in Peer-Review..
CI
01/11Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients, Watching Ed..
AQ
01/11ENDO INTERNATIONAL : at J.P. Morgan Healthcare Conference
PU
01/11ENDO INTERNATIONAL PLC : Regulation FD Disclosure (form 8-K)
AQ
More news
Analyst Recommendations on ENDO INTERNATIONAL PLC
More recommendations
Financials (USD)
Sales 2021 2 940 M - -
Net income 2021 10,2 M - -
Net Debt 2021 6 712 M - -
P/E ratio 2021 2,41x
Yield 2021 -
Capitalization 776 M 776 M -
EV / Sales 2021 2,55x
EV / Sales 2022 2,57x
Nbr of Employees 3 397
Free-Float -
Chart ENDO INTERNATIONAL PLC
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 3,32 $
Average target price 6,17 $
Spread / Average Target 85,7%
EPS Revisions
Managers and Directors
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
Robert Polke Global Head-Operations